Please assess the completion status of the following clinical trial:

Trial Title: Study to Evaluate the Effect on Nitrogen Retention of Two Different Posology Schemes of PKU GOLIKE PLUS 3-16 and Free AAs in Patients With Phenylketonuria

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria:~1. Signed, informed consent obtained prior to being enrolled into the study and prior to starting any data collection. Consent of a legally authorized guardian is required for legally minor patients as defined by local regulation. If the patient is legally a minor, signed written consent shall be obtained from parent(s)/legal guardian and assent obtained from the patient, if applicable.~2. Male or female, aged 3-20 (limits included).~3. Patients with diagnosis of PKU at newborn screening.~4. Patients starting low Phe diet before 1 month of age.~5. Ability and willingness to comply with all study procedures and availability for the duration of the study.~Exclusion Criteria:~1. Known or suspected hypersensitivity to any excipients/components of the investigational products.~2. Treatment with therapy for PKU other than amino-acids supplementation.~3. Patients aged \>12 years old with 4 repeated average values of blood Phe \>600 µM in the previous 6 months.~4. Patients aged \<12 years old with 4 repeated average values of blood Phe \>360 µM in the previous 6 months.~5. Any moderate to severe medical condition, which in the opinion of the Investigator would interfere with the study procedures or study outcome (reasoning to be provided), such as history of clinically significant diseases or malfunctions including, but not limited to, gastrointestinal, renal, hepatic, pulmonary, cardiovascular or endocrine disease, hemophilia, hyperlipidemia, impaired glucose tolerance or diabetes (type 1 or 2), or anemia.~6. History of poor co-operation, non-compliance with medical treatments and diet, or poor adherence to investigational procedures.~7. Any current participation in another clinical trial involving investigational or marketed products in the 3 months prior to the inclusion in this study.~8. Pregnancy or lactation.

- Gender: ALL
- Minimum Age: 3 Years
- Maximum Age: 20 Years
- Healthy Volunteers: f

Study Arms:
- A. One day treatment with 3 self-administrations of GOLIKE PLUS 3-16 (Type: ACTIVE_COMPARATOR): None
- B. One day treatment with 2 self-administrations of GOLIKE PLUS 3-16 (Type: ACTIVE_COMPARATOR): None
- C. One day treatment with 3 self-administrations of free AAs (Type: PLACEBO_COMPARATOR): None
- D. One day treatment with 2 self-administrations of free AAs (Type: PLACEBO_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).